A carregar...

An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability

BACKGROUND: Ocrelizumab, an anti-CD20 humanized monoclonal antibody, reduced disease progression in pivotal trials of patients with relapsing (OPERA I, OPERA II) and primary progressive (ORATORIO) multiple sclerosis (MS). These effects may be particularly important among patients with increased disa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mult Scler J Exp Transl Clin
Main Authors: Wolinsky, Jerry S, Engmann, Natalie J, Pei, Jinglan, Pradhan, Ashish, Markowitz, Clyde, Fox, Edward J
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2020
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7079307/
https://ncbi.nlm.nih.gov/pubmed/32206332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2055217320911939
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!